Visits: 2
A third member of a key FDA panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug, Aduhelm, CNBC has learned. Read More Go To Source
Visits: 2
A third member of a key FDA panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug, Aduhelm, CNBC has learned. Read More Go To Source
Copyright © 2020 | Fastinews.com